How will protein biomarkers influence the future of global healthcare?

Clinical care for the most part still adheres to a one-size-fits-all approach, based on strategies that have been developed for the “average” person, with less consideration of individual differences. The move to more stratified medicine that delivers the right treatment to the right patient at the right time represents the next great movement for global healthcare, but also a colossal challenge for science. Protein biomarker strategies will be key to these developments, helping to us to better understand the biology of disease, to develop new, better and more targeted drugs, and to provide them to the right patients in a more stratified and effective manner.

"Protein Biomarker Symposium 2019" is an invitation-only symposium that will bring together some of the leading researchers in this field, to present their work to an invited audience of like-minded colleagues, and to stimulate a creative discussion on recent progress and future challenges. Welcome to Boston!
Professor Mathias Uhlén

Speaker roster

Mathias Uhlén, PhD

Professor at the Royal Institute of Technology (KTH), Stockholm, Sweden. With over 650 publications to date, his research is focused on protein science, antibody engineering and precision medicine and ranges from basic research to clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. Since 2003, he has led an international effort to systematically map the human proteome with antibodies and to create an open source knowledge-based resource called the Human Protein Atlas (www.proteinatlas.org). Based on the Protein Atlas effort (Uhlen et al, Science, 2015), he has launched a new wellness profiling effort in which individuals have been monitored every three months and analyzed using whole genome sequencing, cell analysis, proteomics, metabolomics and microbiome analysis. Professor Uhlén will host the symposium and deliver the plenary lecture.

Eric Fauman, PhD

Senior Scientific Director and Head, Computational Target Validation at Pfizer. Dr. Eric Fauman received his PhD from the University of California, San Francisco for work on protein structure determination by X-ray crystallography.  He continued his training with post-doctoral work at the University of Michigan, solving the first crystal structure of a cell cycle phosphatase, CDC25A. For the past 20 years, Dr. Fauman has been a computational biologist at Pfizer, working with disease biologists to identify and prioritize drug targets to address unmet medical needs.  He currently leads a team of computational biologists and geneticists dedicated to Computational Target Validation working across multiple disease areas. Dr. Fauman is particularly interested in the interpretation of genome-wide association studies (GWAS) in terms of the underlying biological processes and how this information can be used to understand diseasepathophysiology.

Adam Butterworth, PhD

Lecturer in Cardiovascular Epidemiology at Cambridge University. Following training in Genetics at the University of Cambridge and Genetic Epidemiology at the University of Sheffield, Adam completed a PhD in meta-analysis of genetic association studies of coronary heart disease at the University of Cambridge.  This research was carried out jointly with the PHG Foundation, the MRC Biostatistics Unit, and the Cardiovascular Epidemiology Unit. Since his PhD, Adam has worked in the Cardiovascular Epidemiology Unit, initially as a post-doctoral Research Associate, and since 2012 as a University Lecturer. As well as leading a Genetic Epidemiology team, Adam also oversees the Unit’s PhD students. Adam is the Scientific Coordinator of the EPIC-Heart/EPIC-CVD study, which is a pan-European study of incident coronary disease and stroke including participants from 23 centres across 10 European countries.

Robert Gerszten, MD, PhD

Professor of Medicine at Harvard Medical School and Senior Associate Member of the Broad Institute. Dr Gerszsten is Director of Clinical and Translational Research for the MGH Heart Center. He graduated from the Johns HopkinsUniversity School of Medicine, did his residency at the University ofPennsylvania, and his clinical fellowship in Cardiology at MGH.  Over the past decade, the Gerszten laboratory has built a nationally recognized program in translational research, integrating emerging metabolomic and proteomic approaches towards the identification of novel disease pathways and biomarkers.  An area of particular focus is the application of these tools to identify those most likely to benefit from clinical interventions in cardiometabolic diseases. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study and the TIMI Study Group.

Stefan Blankenberg, MD, PhD

Professor of medicine at the University Heart Center, Hamburg. After studying medicine in Mainz, Frankfurt and New York, he got his MD thesis in 1998. In September 2005, he was nominated as full professor of medicine and faculty member of the Johannes Gutenberg University,Mainz, becoming leading senior physician and deputy director of the Department of Medicine there in 2007. Professor Blankenberg was appointed Director of the Clinic for General and Interventional Cardiology, at the University Heart Center, Hamburg in 2011. He has received numerous awards from institutions such as the German Society of Cardiology & the European Society of Cardiology, amongst many others. His research is focused on individualized cardiovascular medicine with particular focus on acute coronary syndrome and heart failure. Dr. Blankenberg has published numerous papers in journals like NEJM, Nature Genetics, JAMA, Circulation, JACC and European Heart Journal.

Faiez Zannad, MD, PhD

Professor of Therapeutics and Cardiology at INSERM. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995. He entered the European Society of Cardiology (ESC) in 1996 and is past Chairman of the European Society of Cardiology (ESC) Working group on Pharmacology and Drug Therapy and past-President of the French Society of Hypertension. He is the Principal investigator and Member of Steering committees of major large-scale trials in human cardiology (RALES,VALIANT, CIBIS, CAPRICORN, EPHESUS, EMPHASIS-HF). He has served as Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

Agneta Siegbahn, MD, PhD

Senior Professor of Clinical Coagulation Science at Uppsala University and founder and Platform Director of the Clinical Biomarkers Facility at SciLifeLab Uppsala. She obtained her PhD from Uppsala University and has published over 220 original scientific papers and numerous review articles and book chapters. In addition to this major contribution to the CVD literature, she has also played an important role in the increased use of
protein biomarker discovery in academic and clinical research in the Nordic region, setting up and directing the Clinical Biomarkers Facility at SciLifeLab in Uppsala. Among other things, this facility has enabled many Swedish scientists and clinicians to use a proteomics discovery approach in their research, offering Olink’s biomarker panels on a service basis. Professor
Siegbahn currently heads the Clinical Coagulation and Inflammation Science
group at the Department of Medical Sciences.

Jonas Halfvarson, MD, PhD

Associate Professor at Örebro University & Consultant Gastroenterologist at Örebro University Hospital, Sweden. He graduated as MD at Uppsala University, Sweden, before training in gastroenterology at Örebro University Hospital. He obtained his PhD, entitled ‘Inflammatory bowel disease in twins; Studies of genetics and environmental factors’ in 2004. His research focuses on biomarkers in IBD, both from a clinical and from a mechanistic perspective, the latter using twin studies to disentangle the influence of genetic predisposition and exposure to environmental factors. He has published over 100 peer-reviewed papers, as well as contributed to several books on IBD. He has served as vice director for the Swedish national PhD and Postdoctoral program for translational gastroenterology and heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of IBD.

Lars Klareskog, MD, PhD

Professor of Rheumatology at the Karolinska Institute, Stockholm. Dr. Klareskog has had a longstanding interest in the Genetics and Immunology of Rheumatoid Arthritis. He is a medical graduate of Uppsala University where he became Professor at the Clinical Immunology Department in 1990. In 1993, he became  Professor of rheumatology at Karolinska Institute. He is a member of the NobelAssembly and a past member of the Nobel Committee and has acted as the Chairman of the Scientific Board of the Swedish Rheumatism Association since 1997. He has received wide international acclaim for his research in rheumatology and serves on the editorial boards of numerous journals including amongst many, Arthritis & Rheumatism and Current Opinion in Rheumatology.  Dr. Klareskog has published over 300 articles in leading journals including Nature Genetics, New England Journal of Medicine and Nature.

Tomas Olsson

Professor of neurology at Karolinska Institute (KI). He received his MD from University of Linköping, Sweden in 1977 and went on to complete his PhD in Medical Sciences in 1980. He was appointed as Professor of Molecular Medicine in 1995, and since 2008 has held the post of Professor in Neurology at KI. Prof. Olsson is member of the Nobel Assembly, and its Chairman in 2017. He is a member and co-founder of the Swedish Multiple Sclerosis Society and a member of multiple international MS societies. Prof. Olsson is a board member and co-founder of the European school of Neuroimmunology (ESNI), member of the international scientific board of the international congress of Neuroimmunology (ISNI), former executive board member of the international scientific board of the European committee for the treatment of MS. (ECTRIMS) and member of the International Multiple Sclerosis Genetics Consortium (IMSGC).

Henrik Zetterberg

Professor of neurochemistry at the University of Gothenburg, Sweden. He is also professor at University College London, United Kingdom, and a clinical chemist at the Sahlgrenska University Hospital in Gothenburg. Prof. Zetterberg is also head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg. His main research focus and clinical interest is fluid biomarkers for central nervous system disorders including Alzheimer’s disease, for which he has developed new diagnostic tests. He has published more than 800 scientific articles and previously received the Erik K. Fernström Prize for young scientists and the Inga Sandeborg Prize for research on Alzheimer’s disease.

Ulf Gyllensten

Professor of Medical Molecular Genetics at the Department of Immunology, Genetics and Pathology, Uppsala University. He has over 250 peer-reviewed publications and has held many prestigious academic positions, including the editorial boards of several international journals, the priority committees of the Swedish Medical Research Council and Swedish Cancer Society, Director of the world renowned Rudbeck Laboratory and currently, Scientific Director of the Science for Life Laboratory in Uppsala. Professor Gyllensten also holds multiple biotechnology patents, is co-founder of the Swedish biotech companies Dechipher Genetics AB and Quantovir AB and has acted as consultant for both Perkin-Elmer and Roche Molecular Systems.

Erik Ingelsson, MD, PhD

Professor of Medicine at Stanford University. His research area is cardiovascular medicine with a focus on metabolic disturbances such as obesity and insulin resistance, and their role in the development of cardiovascular disease. He is combining large population-based studies with functional in vivo and in vitro studies in a translational framework. Dr. Ingelsson obtained his MD (2000) and PhD (2005) at Uppsala University, Sweden.  He was appointed Professor of Cardiovascular Epidemiology in 2010 at the Karolinska Institute and from 2013-2016, he was a Professor of Molecular Epidemiology at Uppsala University. He was also a Visiting Professor at the Wellcome Trust Centre for Human Genetics at University of Oxford in 2012-2015 and since May 2016, is Professor of Medicine at Stanford University. Professor Inglesson will chair the symposium.

VIEW ALL SPEAKERS

Mathias Uhlén, PhD

Professor at the Royal Institute of Technology (KTH), Stockholm, Sweden. With over 650 publications to date, his research is focused on protein science, antibody engineering and precision medicine and ranges from basic research to clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. Since 2003, he has led an international effort to systematically map the human proteome with antibodies and to create an open source knowledge-based resource called the Human Protein Atlas (www.proteinatlas.org). Based on the Protein Atlas effort (Uhlen et al, Science, 2015), he has launched a new wellness profiling effort in which individuals have been monitored every three months and analyzed using whole genome sequencing, cell analysis, proteomics, metabolomics and microbiome analysis. Professor Uhlén will host the symposium and deliver the plenary lecture.

Eric Fauman, PhD

Senior Scientific Director and Head, Computational Target Validation at Pfizer. Dr. Eric Fauman received his PhD from the University of California, San Francisco for work on protein structure determination by X-ray crystallography.  He continued his training with post-doctoral work at the University of Michigan, solving the first crystal structure of a cell cycle phosphatase, CDC25A. For the past 20 years, Dr. Fauman has been a computational biologist at Pfizer, working with disease biologists to identify and prioritize drug targets to address unmet medical needs.  He currently leads a team of computational biologists and geneticists dedicated to Computational Target Validation working across multiple disease areas including cardiovascular and metabolic diseases, neurodegeneration, autoimmune diseases, rare diseases and oncology. Dr. Fauman is particularly interested in the interpretation of genome-wide association studies (GWAS) in terms of the underlying biological processes and how this information can be used to understand disease pathophysiology.

Adam Butterworth, PhD

Lecturer in Cardiovascular Epidemiology at Cambridge University. Following training in Genetics at the University of Cambridge and Genetic Epidemiology at the University of Sheffield, Adam completed a PhD in meta-analysis of genetic association studies of coronary heart disease at the University of Cambridge.  This research was carried out jointly with the PHG Foundation, the MRC Biostatistics Unit, and the Cardiovascular Epidemiology Unit. Since his PhD, Adam has worked in the Cardiovascular Epidemiology Unit, initially as a post-doctoral ResearchAssociate, and since 2012 as a University Lecturer. As well as leading a Genetic Epidemiology team, Adam also oversees the Unit’s PhD students. Adam is the Scientific Coordinator of the EPIC-Heart/EPIC-CVD study, which is a pan-European study of incident coronary disease and stroke including participants from 23 centres across 10 European countries.

Robert Gerszten, MD, PhD

Professor of Medicine at Harvard Medical School and Senior Associate Member of the Broad Institute. Dr Gerszsten is Director of Clinical and Translational Research for the MGH Heart Center. He graduated from the Johns HopkinsUniversity School of Medicine, did his residency at the University ofPennsylvania, and his clinical fellowship in Cardiology at MGH.  Over the past decade, the Gerszten laboratory has built a nationally recognized program in translational research, integrating emerging metabolomic and proteomic approaches towards the identification of novel disease pathways and biomarkers.  An area of particular focus is the application of these tools to identify those most likely to benefit from clinical interventions in cardiometabolic diseases. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study and the TIMI Study Group.

Stefan Blankenberg, MD, PhD

Professor of medicine at the University Heart Center, Hamburg. After studying medicine in Mainz, Frankfurt and New York, he got his MD thesis in 1998. In September 2005, he was nominated as full professor of medicine and faculty member of the Johannes Gutenberg University,Mainz, becoming leading senior physician and deputy director of the Department of Medicine there in 2007. Professor Blankenberg was appointed Director of the Clinic for General and Interventional Cardiology, at the University Heart Center, Hamburg in 2011. He has received numerous awards from institutions such as the German Society of Cardiology & the European Society of Cardiology, amongst many others. He has been a member of many German and international organizations, such as program chair of the German Society of Cardiology and the steering Committee of the MORGAM Study. His research is focused on individualized cardiovascular medicine with particular focus on acute coronary syndrome and heart failure. Dr. Blankenberg has published numerous papers in journals like NEJM, Nature Genetics, JAMA, Circulation, JACC and European Heart Journal.

Faiez Zannad, MD, PhD

Professor of Therapeutics and Cardiology at INSERM. He is at the Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU) of Nancy since 1995. He entered the European Society of Cardiology (ESC) in 1996 and is past Chairman of the European Society of Cardiology (ESC) Working group on Pharmacology and Drug Therapy and past-President of the French Society of Hypertension. He is the Principal investigator and Member of Steering committees of major large-scale trials in human cardiology (RALES,
VALIANT, CIBIS, CAPRICORN, EPHESUS, EMPHASIS-HF). He has served as Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.

Agneta Siegbahn, MD, PhD

Senior Professor of Clinical Coagulation Science at UppsalaUniversity and founder and Platform Director of the Clinical BiomarkersFacility at SciLifeLab Uppsala. She obtained her PhD from Uppsala Universityand has published over 220 original scientific papers and numerous reviewarticles and book chapters. In addition to this major contribution to the CVDliterature, she has also played an important role in the increased use ofprotein biomarker discovery in academic and clinical research in the Nordicregion, setting up and directing the Clinical Biomarkers Facility at SciLifeLabin Uppsala. Among other things, this facility has enabled many Swedishscientists and clinicians to use a proteomics discovery approach in theirresearch, offering Olink’s biomarker panels on a service basis. ProfessorSiegbahn currently heads the Clinical Coagulation and Inflammation Sciencegroup at the Department of Medical Sciences.

Jonas Halfvarson, MD, PhD

Associate Professor at Örebro University & Consultant Gastroenterologist at Örebro University Hospital, Sweden. He graduated as MD at Uppsala University, Sweden, before training in gastroenterology at Örebro University Hospital. He obtained his PhD, entitled ‘Inflammatory bowel disease in twins; Studies of genetics and environmental factors’ in 2004. His research focuses on biomarkers in IBD, both from a clinical and from a mechanistic perspective, the latter using twin studies to disentangle the influence of genetic predisposition and exposure to environmental factors. He has published over 100 peer-reviewed papers, as well as contributed to several books on IBD. He has served as vice director for the Swedish national PhD and Postdoctoral program for translational gastroenterology, heads the taskforce for genetics and pathophysiology at the Swedish Organisation for the Study of IBD, and is the Scientific Director of the Swedish IBD registry (SWIBREG). Dr Halfvarson is also a board member of the International Organization for the study of Inflammatory Bowel Disease (IOIBD).

Lars Klareskog, MD, PhD

Professor of Rheumatology at the Karolinska Institute, Stockholm. Dr. Klareskog has had a long standing interest in the Genetics and Immunology of Rheumatoid Arthritis. He is a medical graduate of Uppsala University where he became Professor at the Clinical Immunology Department in 1990. In 1993, he became  Professor of rheumatology at Karolinska Institute. He is a member of the Nobel Assembly and a past member of the Nobel Committee and has acted as the Chairman of the Scientific Board of the Swedish Rheumatism Association since 1997. He has received wide international acclaim for his research in rheumatology and serves on the editorial boards of numerous journals including amongst many, Arthritis & Rheumatism and Current Opinion in Rheumatology.  Dr. Klareskog has published over 300 articles in leading journals including Nature Genetics, New England Journal of Medicine and Nature.

Tomas Olsson

Professor of neurology at Karolinska Institute (KI). He received his MD from University of Linköping, Sweden in 1977 and went on to complete his PhD in Medical Sciences in 1980. He was appointed as Professor of Molecular Medicine in 1995, and since 2008 has held the post of Professor in Neurology at KI. Prof. Olsson is member of the Nobel Assembly, and its Chairman in 2017. He is a member and co-founder of the Swedish Multiple Sclerosis Society and a member of multiple international MS societies. Prof. Olsson is a board member and co-founder of the European school of Neuroimmunology (ESNI), member of the international scientific board of the international congress of Neuroimmunology (ISNI), former executive board member of the international scientific board of the European committee for the treatment of MS. (ECTRIMS) and member of the International Multiple Sclerosis Genetics Consortium (IMSGC).

Henrik Zetterberg

Professor of neurochemistry at the University of Gothenburg, Sweden. He is also professor at University College London, United Kingdom, and a clinical chemist at the Sahlgrenska University Hospital in Gothenburg. Prof. Zetterberg is also head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg. His main research focus and clinical interest is fluid biomarkers for central nervous system disorders including Alzheimer’s disease, for which he has developed new diagnostic tests. He has published more than 800 scientific articles and previously received the Erik K. Fernström Prize for young scientists and the Inga Sandeborg Prize for research on Alzheimer’s disease.

Ulf Gyllensten

Professor of Medical Molecular Genetics at the Department of Immunology, Genetics and Pathology, Uppsala University. He has over 250 peer-reviewed publications and has held many prestigious academic positions, including the editorial boards of several international journals, the priority committees of the Swedish Medical Research Council and Swedish Cancer Society, Director of the world renowned Rudbeck Laboratory and currently, Scientific Director of the Science for Life Laboratory in Uppsala. Professor Gyllensten also holds multiple biotechnology patents, is co-founder of the Swedish biotech companies Dechipher Genetics AB and Quantovir AB and has acted as consultant for both Perkin-Elmer and Roche Molecular Systems.

Erik Ingelsson, MD, PhD

Professor of Medicine at Stanford University. His research area is cardiovascular medicine with a focus on metabolic disturbances such as obesity and insulin resistance, and their role in the development of cardiovascular disease. He is combining large population-based studies with functional in vivo and in vitro studies in a translational framework. Dr. Ingelsson obtained his MD (2000) and PhD (2005) at Uppsala University, Sweden.  He was appointed Professor of Cardiovascular Epidemiology in 2010 at the Karolinska Institute and from 2013-2016, he was a Professor of Molecular Epidemiology at Uppsala University. He was also a Visiting Professor at the Wellcome Trust Centre for Human Genetics at University of Oxford in 2012-2015 and since May 2016, is Professor of Medicine at Stanford University. Professor Inglesson will chair the symposium.

Practical information

Venue – Nobel Forum

This is the buildiing where the Nobel Secretariat carries on its daily work. It is also here that the Nobel Committee announces the year’s Laureate in Physiology or Medicine. With the Nobel Forum, the Karolinska Institute has also gained a meeting place for scientists from all over the world. See more information here

Address:
Nobel Forum
Nobels väg 1
17165 Solna

Experience Stockholm

If you are coming to the symposium from out of town and have the opportunity, there is no better time to explore the beautiful city of Stockholm than Midsummer week, when the days stretch out until late into the evening. Click the link below to find the top ten things to do in Stockholm!
Official City Guide:
VIEW AGENDA
09:30 - 10:00
Registration, Coffee & Breakfast
10:00 - 10:05
Opening remarks
Professor Ingelsson will welcome everyone to the symposium and run through some practical information and logistical details for the day.
Erik Ingelsson

Agenda Session 1 - Systems Biology & Big Data

10:05 - 10:45
The Human Protein Atlas - implications for human biology, drug development and precision medicine
The Human Protein Atlas (HPA) is a Swedish-based program with the aim to map of all the human proteins in cells, tissues and organs using integration of various omics technologies. In this presentation, Dr Uhlen will present the implications of this work for the understanding of human biology  and the use of the open access knowledge resource for drug development with a focus on the profiling of wellness and disease by a multitude of omics platforms, including whole genome sequencing, medical imaging. clinical chemistry and new ways to profile the human blood proteins, such as the Olink technology.
Mathias Uhlen
10:45 - 11:10
How the genome manipulates the proteome: Lessons gleaned from all published trans pQTLs
Proteins are responsible for nearly every function of biology, yet they are ultimately regulated by the genome.  How is it that tiny atomic changes buried deep within the nucleus of the cell can manifest in alterations in the function and localization of proteins throughout the body.  By combining the power of genome-wide association studies (GWAS) with protein quantification methodologies we can identify individual DNA variants that associate with differences in levels of specific proteins. In this presentation I review all published protein QTL (pQTL) GWAS studies to better understand and categorize the various ways in which DNA changes can affect protein
levels.  In particular, trans-pQTLs, in which the DNA change is far from the gene encoding the protein biomarker, can confirm and expand our understanding of the biological pathways involved in regulating proteinactivity.
Eric Fauman
11:10 - 11:35
Combining proteomics and genomics to inform disease aetiology and therapeutic target prioritisation
I will show how we combined genomic and proteomic data in the INTERVAL study to identify hundreds of novel genetic associations, enhancing our understanding of the genetic architecture of protein levels. By integrating with GWAS results for a wide range of complex diseases we identified causal pathways for diseases such as inflammatory bowel disease and vasculitis. Mendelian randomisation analyses pinpointed specific interleukin genes as causally relevant to atopic dermatitis and suggested a surprising causal association for MMP12 with coronary heart disease, indicating a potential safety signal for MMP12 inhibitors. Finally, I will touch on the challenges of interpreting findings across proteomic platforms
Adam Butterworth
11:35 - 11:55
Panel discussion
Mathias Uhlén, Eric Fauman and Adam Butterworth will discuss some of the main issues brought up during the session and take any questions from the audience
11:55 - 12:40
Lunch
12:40 - 13:05
Development of protein biomarker tests for gynaecological cancer
We have identified protein biomarkers for cervical, endometrial and ovarian cancer, using a two-step study design and the Olink multiplex panels. Based on the results of discovery and replication cohort analyses, multiplex assays are developed for clinical validation studies.
Ulf Gyllensten

Agenda Session 2 - Clinical applications in cardiovascular diseases

13:05 - 13:30
Mining the Blood for New Cardiometabolic Markers and Pathways
Because metabolites and proteins are downstream of genetic variation and   transcriptional changes, they
serve as “proximal reporters” of physiology and may be highly relevant biomarkers for human cardiometabolic diseases. Emerging data from our laboratory and others also suggest that circulating metabolites and proteins active G protein coupled receptors and other ligands to modulate human physiology. Thus, we take observations in humans and then turn to cell and animal based systems to test for causal relationships (“retro-translation”).  Our research incorporates basic molecular and cell biology, genetics, chemistry, mass spectrometry and bioinformatics, all with a foundation in clinical medicine.
Robert Gerszten
13:30 - 13:55
Impact of molecular markers and biomarkers on cardiovascular risk stratification and therapy selection
More details to follow  when available
Stefan Blankenberg
13:55 - 14:20
Toward precision medicine for heart failure patients: Latest results from EU programs.
EU programs such as BIOSATAT, MEDIA, FIBROTARGETS and HOMAGE have collected an important set of omics data which are helping identifying novel mechanistic pathways which can serve as new potential biotargets for the prevention and treatment of heart failure (HF). These and other programs are providing deep insight into possibilities for segmenting the HF syndrome in discrete phenotypes that may identify responders to current and novel therapies, hence creating novel opportunities for precision medicine trials for HF patients.
Faiez Zanad
14:20- 14:45
Prognostic biomarkers associated with cardiovascular events in atrial fibrillation
In atrial fibrillation (AF) treatment with oral anticoagulation is a balance between reduction in stroke and increase in major bleeding. We have previously shown that biomarkers provide important prognostic information concerning these events in AF. Two novel biomarker-based scores, the ABC risk scores, to improve the prognostication of stroke and major bleeding will be presentaed. We have also used the Olink PEA multiplex
technology to screen for additional prognostic biomarkers in a large cohort of patients with AF.
Agneta Siegbahn
14:45 - 15:05
Panel discussion
Robert Gerzsten, Stefan Blankenberg, Faiez Zannad and Agenta Siegbahn will discuss some of the main issues brought up during the session and take any questions from the audience
15:05 - 15:35
Coffee break

Agenda Session 3 - Clinical applications in other disease areas

15:35 - 16:00
Will biomarkers reshape the future landscape of IBD?
Predictive, diagnostic and prognostic markers of inflammatory bowel disease (IBD) are emerging, but only a few biomarkers have yet reached clinical practice. Advances within microbiomics, genomics, transcriptomics and proteomics are expected to change the landscape of IBD.
Jonas Halfvarson
16:00 - 16:25
Towards prevention of rheumatoid arthritis; Use of biomarkers to predict future onset of disease
Rheumatoid arthritis is one of several autoimmune diseases where autoimmunity precedes development of inflammation and tissue destruction. The lecture will discuss how use of biomarkers may enable identification of individuals at high risk for disease and mechanisms involved in disease development. Such knowledge will enable development of prevention of autoimmune disease like RA.
Lars Klareskog
16:25 - 16:50
Plasma biomarkers in multiple sclerosis, a new attractive option for diagnosis and prognosis
   
Tomas Olsson
16:50 - 17:15
The neuroinflammatory signature of CSF in neurodegenerative diseases as compared to multiple sclerosis
The presentation details a biomarker-based dissection of the role of neuroinflammation in neurodegenerative and neuroinflammatory diseases.
Henrik Zetterberg
17:15 - 17:35
Panel discussion
Jonas Halfvarson, Lars Klareskog, Tomas Olsson and Henrik Zetterberg will discuss some of the main issues brought up during the session and take any questions from the audience
18:00
Meeting ends
Meeting wrap-up and any final practical information regarding the evening's entertainment for those attending
19:00 - 22:00
Boat trip and dinner
A chance to relax and discuss with your fellow attendees on a 3 hour cruise in the beautiful Stockholm archipelago. Buses will be provided to take you to the boat from the Nobel Forum, and also to the Haymarket hotel afterwards
Can we help you with something?
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
About the conference
"Precision Proteomics to Drive Personalized Medicine" is an international one-day symposium, hosted by Professor Mathias Uhlén and sponsored by Olink Proteomics. The meeting will focus on how protein biomarker-based strategies can influence and drive the development of a more stratified approach to healthcare, and help to realize the potential of "precision medicine". As well as featuring presentations from some of the world's leading researchers in this field, the event aims to provide a forum where academia and industry can exchange views and forge collaborations, interactions that are essential for the future of global healthcare. Attendance is strictly by invitation only, but if you have any questions or comments about this or future events, please use the simple form above.